To the content

AOP Health: Roland Bindeus becomes Senior Director Commercial

November 8th 2023

Vienna, 08.11.2023. The Vienna-based pharmaceutical company AOP Orphan Pharmaceuticals GmbH (AOP Health), which specializes in rare diseases and critical care medicine, is repositioning itself strategically. In order to offer patients and healthcare professionals state-of-the-art therapy concepts not only today, but also in the future, AOP Health is introducing new structures to achieve more efficient operations and growth.

Dr. Roland Bindeus

We are continuously developing our therapy concepts in close collaboration with international experts. To reliably execute this complex task as we grow globally, we need certain competencies and processes. I am very pleased to be putting these in place together with my team.

Internal Promotion 

Roland Bindeus (45 years old), who has been promoted to Senior Director Commercial at the headquarters in Vienna, is responsible for this strategic development. Born in Austria, he studied biochemistry at the University of Vienna and has over 15 years of experience in national and international positions in the pharmaceutical industry. He has been with AOP Health since 2016, most recently serving as Director for the German-speaking countries.

In his new role, Bindeus will oversee the four therapy areas of Hemato-Oncology, Cardiology and Pulmonology, Critical Care Medicine, and Neurology and Metabolic Disorders. With the introduction of Commercial Excellence, he will establish a new unit focusing on business data analysis, digital applications, global congress and conference management, and the coordination of standards and training. Roland Bindeus will report to Petra Lanz, Chief Commercial Officer at AOP Health.

About AOP Health

The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. The claim “Needs. Science. Trust.” sums up the foundation of the Group’s success: establishing trust through a continually high level of investment in research and development and a highly consistent and pragmatic orientation towards the needs of all stakeholders – especially the patients and their families as well as the healthcare professionals treating them.

Press Contact.

Mag. Nina Roth, MAS

Head of Corporate Communications

To the main navigation